Pro-Dex (PDEX) Given a $20.00 Price Target by Ascendiant Capital Markets Analysts

Ascendiant Capital Markets set a $20.00 price target on Pro-Dex (NASDAQ:PDEX) in a research note published on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

Separately, ValuEngine raised Pro-Dex from a hold rating to a buy rating in a report on Monday, February 4th.

PDEX traded up $0.11 during trading hours on Tuesday, hitting $13.85. The stock had a trading volume of 205 shares, compared to its average volume of 41,590. Pro-Dex has a 1 year low of $6.05 and a 1 year high of $17.95. The firm has a market cap of $56.47 million, a P/E ratio of 17.38 and a beta of 1.07. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.60 and a current ratio of 5.88.

In other Pro-Dex news, Director Raymond E. Cabillot sold 7,451 shares of Pro-Dex stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $16.05, for a total transaction of $119,588.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond E. Cabillot sold 8,977 shares of Pro-Dex stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $17.66, for a total value of $158,533.82. The disclosure for this sale can be found here. Insiders have sold a total of 52,639 shares of company stock valued at $879,209 in the last ninety days. Insiders own 41.70% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its holdings in Pro-Dex by 3.7% during the 1st quarter. Renaissance Technologies LLC now owns 47,300 shares of the medical instruments supplier’s stock valued at $685,000 after buying an additional 1,700 shares in the last quarter. Wells Fargo & Company MN purchased a new position in Pro-Dex during the 1st quarter valued at about $47,000. BlackRock Inc. grew its holdings in Pro-Dex by 27.5% during the 1st quarter. BlackRock Inc. now owns 15,766 shares of the medical instruments supplier’s stock valued at $228,000 after buying an additional 3,397 shares in the last quarter. Alambic Investment Management L.P. grew its holdings in Pro-Dex by 6.2% during the 1st quarter. Alambic Investment Management L.P. now owns 73,583 shares of the medical instruments supplier’s stock valued at $1,065,000 after buying an additional 4,291 shares in the last quarter. Finally, Advisor Group Inc. purchased a new position in Pro-Dex during the 1st quarter valued at about $82,000. 10.51% of the stock is owned by institutional investors and hedge funds.

Pro-Dex Company Profile

Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services.

Recommended Story: What are municipal bonds?

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.